Evgen Pharma Plc
Evgen Pharma is an AIM listed clinical stage drug development company developing medicines for the treatment of multiple diseases focusing on Oncology.
Our lead programme has completed a study in patients with oestrogen-positive (ER+) metastatic breast cancer and will be entering a Ph2 study in Glioma patients (Glioblastoma multiforme) in H2 2022.
We are open to partnering discussions as well as in-licensing/acquisition opportunities in cancer therapeutics and supportive care.
Karma Oncology is a specialised oncology clinical development company headquartered in Scotland with offices in Netherlands and USA. We offer a complete range of development services from clinical development planning, protocol design and authoring, strategic country/site selection, regulatory submissions, through to clinical trial execution and reporting.
Adaptable - We can provide selected individual services, and extend to full-service global CRO capabilities clients require. Our size allows us to be flexible, innovative and responsive to individual sponsor requirements and to adhere strictly to sponsor specified development timelines.
Reliable - Our Project Managers have extensive oncology experience, our monitors are professional, mature 'career' CRAs - not trainees - and we have the lowest staff turnover in the industry (<5%). Many of our staff come from a nursing or medical background, and for international studies we use CRAs native to their country.
Motivated - Our team has successfully completed programs in a broad range of solid tumour and hematologic indications utilising an array of different therapeutic approaches including immunotherapy and cell therapies (autologous, CAR-T and CAR-NK).
Accountable – The Karma team focus on delivering quality while respecting sponsor timelines (not internal timelines) and will do what it takes to do so.Twitter Account @KarmaOncology